Navigating the Complex Treatment Landscape of Intermediate and Advanced HCC: A Think Tank Activity
Released On
September 16, 2024
Expires On
September 16, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topics
Liver disease/cancer, Oncology
Provider Statement
This activity is provided by Integrity CE, LLC.
Disclosure of Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the professional educational needs of medical, surgical, and radiation oncologists, gastroenterologists, interventional radiologists, and advanced practice professionals who treat and manage patients with gastrointestinal cancers.
Program Overview
With the accelerated expansion of the treatment landscape of intermediate and advanced hepatocellular carcinoma (HCC), several practical challenges have emerged in clinical practice. An example of this is the challenge of identifying patients with intermediate HCC who would benefit from local-regional treatment with TACE/TARE or a combination approach with TACE/TARE + IO. Multidisciplinary care is critical to optimize outcomes for these patients.
This program features a moderated discussion among a panel of experts: a surgeon, a hepatologist, and a medical oncologist, all involved in the management and treatment of patients with HCC.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Implement novel first-line regimens, including multimodal combination and sequential treatment strategies, in the treatment of patients with intermediate HCC based on emerging evidence from clinical trials
- Integrate emerging therapies and novel combination regimens in the treatment of patients with advanced HCC to improve treatment outcomes
Faculty
PROGRAM CHAIR
Michael Pishvaian, MD, PhD
Director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia
PANEL
Richard S. Finn, MD
Professor of Medicine, Hematology/Oncology
Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
Riad Salem, MD
Professor of Radiology, Medicine, and Surgery
Vice-Chair, Image-Guided Therapy
Chief, Vascular and Interventional Radiology
Northwestern University
Chicago, Illinois
Amit Singal, MD, MS
Professor of Medicine
Chief of Hepatology and Director of Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Richard S. Finn, MD
Consultant: AstraZeneca, Bayer, CStone, Eisai, Eli Lilly, Exelixis, Merck, Novartis, Pfizer, Roche/Genentech, Zai Labs
Research Grants: Bayer, Eisai, Eli Lilly, Pfizer, Merck, Roche/Genentech
Michael Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Steering Committees: Astellas, Merck, Renovo Rx
CME Activity: Astellas
Travel: Astellas, Renovo Rx
Stock: Perthera
Riad Salem, MD
Consultant: AstraZeneca, Becton Dickinson, Boston Sciences, Cook, Eisai, Genentech, Siemens, Sirtex, Terumo
Amit Singal, MD, MS
Consultant: AstraZeneca, Bayer, Boston Scientific, Eisai, Exact Sciences, Exelixis, FujiFilm Medical Sciences, Glycotest, HistoSonics, Merck Genentech, Sirtex
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of September 16, 2024 through September 16, 2025, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].